Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 8
Evotec AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 9
Evotec AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 10
Evotec AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 11
Evotec AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 12
Evotec AG, Medical Devices Deals, 2012 to YTD 2018 14
Evotec AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 15
Evotec AG, Pharmaceuticals & Healthcare, Deal Details 21
Venture Financing 21
Forge Therapeutics Raises USD15 million in Series A Financing 21
Eternygen Raises USD8.4 Million in Series A Financing 22
Carrick Therapeutics Raises USD95 Million in Venture Financing 23
Topas Therapeutics Raises USD15.8 Million in Series A Financing 25
Partnerships 27
Evotec and APEIRON Biologics Enters into Licensing Agreement with Sanofi 27
Ferring Pharma and Evotec Enter into Research Partnership 28
Evotec and Almirall Enter into Research Agreement 29
Evotec and Celgene Enter into Partnership 30
Centogene and Evotec Enter into Co-Development Agreement 31
Evotec Enters into Co-Development Agreement with Novo Nordisk 32
Evotec Enters into R&D Agreement with Sanofi 33
Evotec and Artesian Therapeutics Enter into Agreement 34
Evotec and Oxford Bioscience Partners Enter into Co-Development Agreement 35
Evotec and Celgene Enter into Drug Discovery and Development Partnership 36
Evotec Enters into Partnership with Carna Biosciences 37
Evotec Enters into Partnership with Petra Pharma 38
Evotec Enters into Agreement with U3 Pharma 39
Evotec Enters into Research Agreement with Center for Regenerative Therapies Dresden 40
Evotec Enters into Partnership with University of Bristol, University of Cambridge and Mario Negri Institute for Pharmacological Research 41
Evotec and Tesaro Enter into Agreement 43
Forge Therapeutics and Evotec Enter into Partnership 44
Evotec and Abivax Enter into Partnership 45
Evotec Enters into Partnership with Fraunhofer 46
Evotec Enters into Agreement with Censo Biotech 47
Bioversys and Aptuit Enter into Partnership 48
Dementia Discovery Fund and Aptuit Enter into Partnership 49
Aptuit Enters into Agreement with Massachusetts General Hospital 50
Evotec Enters into Agreement with Asahi Kasei Pharma 51
Evotec Forms Joint Venture with MaRS Innovation 52
Chronos Therapeutics Partners with Aptuit 53
Aptuit Enters into Agreement with Chiesi Farmaceutici 54
Evotec Expands Agreement with Storm Therapeutics 55
Evotec Expands Research Agreement with Celgene 56
Evotec Enters into Agreement with Forge Therapeutics 57
Evotec Partners with Merck 58
Evotec Partners with University of Oxford, Oxford University Innovation and Oxford Sciences Innovation 59
Evotec Enters into Agreement with C4X Discovery 60
Evotec Enters into Research Agreement with Inserm Transfert 61
Bayer Enters into Partnership with Evotec 62
Evotec Enters into Agreement with Antibiotic Research UK 63
Aptuit Enters into Agreement with Dimension Therapeutics 64
Trianni Enters into Agreement with Evotec 65
Evotec Forms Partnership with Ex Scientia 66
Evotec Partners with Pierre Fabre Labs 67
Icagen Partners with Aptuit 68
Evotec Partners with UCB 69
Evotec Extends its Agreement with Spero Therapeutics 70
Evotec Enters into Co-Development Agreement with Beyond Batten Disease Foundation 71
Evotec Enters into Research Agreement with Sanofi 72
Gladstone Institutes Enters into Joint Venture with Dolby Family Ventures and Evotec 73
Evotec Enters into Agreement with Facio Therapies 74
Second Genome Enters into Agreement with Evotec 75
SAMDI Tech Enters into Agreement with Exquiron 76
Evotec Enters into Research Agreement with C4X Discovery 77
Evotec Enters into Research Agreement with Ohio State University 78
Evotec Extends Research Agreement with C4X Discovery 79
Evotec to Enter into Co-Development Agreement with Sanofi 80
Evotec Enters into Research Agreement with C4X Discovery for NMR Technology 82
Rheumatech Enters into Development Agreement with Evotec 83
Euprotec Enters Into Agreement With Cantab Anti-infectives To Develop Antibiotics 84
Evotec Enters into Co-Development Agreement with Eternygen 85
Evotec Enters Into Agreement With Panion For Developing Chronic Pain Treatments 86
Evotec Enters into Agreement with Padlock Therapeutics 87
Evotec Extends Agreement with Padlock Therapeutics 88
Evotec Enters Into Research Agreement With Yale University For Cancer Therapy 89
Evotec Enters Into Co-Development Agreement With Johnson & Johnson 90
Evotec Enters Into Research Agreement With Leukemia & Lymphoma Society 91
Evotec Enters Into Research Agreement With Harvard University For Enteroendocrine Mechanisms 92
Evotec Enters Into Research Agreement With Harvard Stem Cell Institute For Amyotrophic Lateral Sclerosis 93
Evotec Enters Into Research Agreement With Harvard University To Develop Antibacterial Drugs 94
Evotec Enters Into Co-Development Agreement With Dana-Farber For Cancer Epigenetics 95
Evotec Enters Into Research Agreement With Apeiron Biologics For Cancer Immunotherapy 96
Evotec Enters Into Co-Development Agreement With Probiodrug For Glutaminyl Cyclase 97
Evotec Enters Into Agreement With Haplogen To Develop Drugs For Infectious Diseases 98
Apredica Enters Into Research Agreement With Pfizer 99
Bayer Extends its Co-Development Agreement with Evotec for Endometriosis Drugs 100
Evotec Enters Into Agreement With 4-Antibody For Antibody Detection 101
Evotec Enters Into Co-Development Agreement With IR Pharma 102
Evotec Enters Into Co-Development Agreement With Harvard University And BWH 103
Licensing Agreements 105
Bayer Enters into Licensing Agreement with Haplogen and Evotec 105
Evotec Enters into Licensing Agreement with ERS Genomics 106
Evotec Enters into Licensing Agreement with Ncardia 107
Evotec Enters Into Licensing Agreement With Debiopharm 108
Evotec Enters Into Licensing Agreement With AstraZeneca For Kidney Disease Treatment 109
Evotec Enters Into Licensing Agreement With Janssen Pharma For NMDA Antagonists 110
Evotec Enters into Licensing Agreement with Broad Institute 112
Pfizer Enters into Licensing Agreement with Evotec 113
Cevec Pharma Enters Into Licensing Agreement With CCS Cell Culture Service 114
Cyprotex Enters Into Licensing Agreement With Sigma For Zinc Finger Nuclease Technology 115
Evotec And Harvard University Enter Into Licensing Agreement With Janssen Pharma For Beta-Cell Regeneration Candidates 116
Evotec Enters Into Licensing Agreement With Zhejiang Conba Pharma For EVT 401 118
Equity Offering 119
Facio Therapies Raises USD5.4 Million in Equity Financing 119
Evotec to Raise USD96.4 Million in Private Placement of Shares 120
Evotec Receives Investment from Ellersbrook 121
Evotec Spin Out from Topas Therapeutics 122
Evotec Completes Private Placement Of Shares For US$40 Million 123
Asset Transactions 125
Catalent Pharma Completes Acquisition Of Clinical Trial Supplies Business From Aptuit For US$410 Million 125
Acquisition 126
Evotec Acquires Minority Stake in Exscientia for USD17.6 Million 126
Evotec Acquires Aptuit for USD300 Million 127
Evotec Acquires Cyprotex for USD68 Million 129
Aptuit Acquires Kuecept 131
Aptuit Acquires Exquiron Biotech 132
Albany Molecular Research Acquires SSCI from Aptuit for USD36 Million 133
Albany Molecular Research Acquires Aptuit Glasgow from Aptuit for USD24 Million 134
Evotec Acquires Euprotec 135
Evotec Acquires Bionamics, Asset Management Company 136
Apredica Acquires CeeTox, In-Vitro Toxicological Assays And Screening Data Provider, For Up To US$6 Million 137
Evotec Acquires CCS Cell Culture Service, Contract Research Organization 138
Evotec Acquires DeveloGen For USD18 Million 139
Evotec AG – Key Competitors 141
Evotec AG – Key Employees 142
Evotec AG – Locations And Subsidiaries 143
Head Office 143
Other Locations & Subsidiaries 143
Joint Venture 144
Recent Developments 145
Financial Announcements 145
Aug 09, 2018: Evotec reports first half-year 2018 results and corporate updates 145
May 09, 2018: Evotec Reports First Quarter 2018 Results and Provides Corporate Update 149
Nov 08, 2017: Evotec announces first nine-month 2017 results and corporate update 151
Aug 10, 2017: Evotec Announces First Half Year 2017 Results 154
May 10, 2017: Evotec Announces First Quarter 2017 Results and Corporate Update 157
Mar 28, 2017: Evotec fiscal year results 2016: Leading innovation efficiency & First-in-class drug discovery 160
Government and Public Interest 164
Feb 21, 2017: Evotec: ‘LAB282′ awarded first projects 164
Product News 165
09/20/2017: Sanofi and NIH researchers develop “three-in-one” antibodies as a potential breakthrough intervention for HIV/AIDS 165
Other Significant Developments 166
Mar 27, 2018: Evotec plans conversion into European Company (SE) 166
Mar 26, 2018: Evotec Launches INDIGO, A Unique Integrated Drug Development Solution for Accelerating Early Drug Candidates into the Clinic 167
Sep 08, 2017: European Investment Bank supports Evotec´s Innovate strategy with € 75 m loan 168
Appendix 169
Methodology 169
About GlobalData 169
Contact Us 169
Disclaimer 169
Evotec AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Evotec AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 9
Evotec AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 10
Evotec AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 11
Evotec AG, Deals By Therapy Area, 2012 to YTD 2018 12
Evotec AG, Medical Devices Deals, 2012 to YTD 2018 14
Evotec AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 15
Forge Therapeutics Raises USD15 million in Series A Financing 21
Eternygen Raises USD8.4 Million in Series A Financing 22
Carrick Therapeutics Raises USD95 Million in Venture Financing 23
Topas Therapeutics Raises USD15.8 Million in Series A Financing 25
Evotec and APEIRON Biologics Enters into Licensing Agreement with Sanofi 27
Ferring Pharma and Evotec Enter into Research Partnership 28
Evotec and Almirall Enter into Research Agreement 29
Evotec and Celgene Enter into Partnership 30
Centogene and Evotec Enter into Co-Development Agreement 31
Evotec Enters into Co-Development Agreement with Novo Nordisk 32
Evotec Enters into R&D Agreement with Sanofi 33
Evotec and Artesian Therapeutics Enter into Agreement 34
Evotec and Oxford Bioscience Partners Enter into Co-Development Agreement 35
Evotec and Celgene Enter into Drug Discovery and Development Partnership 36
Evotec Enters into Partnership with Carna Biosciences 37
Evotec Enters into Partnership with Petra Pharma 38
Evotec Enters into Agreement with U3 Pharma 39
Evotec Enters into Research Agreement with Center for Regenerative Therapies Dresden 40
Evotec Enters into Partnership with University of Bristol, University of Cambridge and Mario Negri Institute for Pharmacological Research 41
Evotec and Tesaro Enter into Agreement 43
Forge Therapeutics and Evotec Enter into Partnership 44
Evotec and Abivax Enter into Partnership 45
Evotec Enters into Partnership with Fraunhofer 46
Evotec Enters into Agreement with Censo Biotech 47
Bioversys and Aptuit Enter into Partnership 48
Dementia Discovery Fund and Aptuit Enter into Partnership 49
Aptuit Enters into Agreement with Massachusetts General Hospital 50
Evotec Enters into Agreement with Asahi Kasei Pharma 51
Evotec Forms Joint Venture with MaRS Innovation 52
Chronos Therapeutics Partners with Aptuit 53
Aptuit Enters into Agreement with Chiesi Farmaceutici 54
Evotec Expands Agreement with Storm Therapeutics 55
Evotec Expands Research Agreement with Celgene 56
Evotec Enters into Agreement with Forge Therapeutics 57
Evotec Partners with Merck 58
Evotec Partners with University of Oxford, Oxford University Innovation and Oxford Sciences Innovation 59
Evotec Enters into Agreement with C4X Discovery 60
Evotec Enters into Research Agreement with Inserm Transfert 61
Bayer Enters into Partnership with Evotec 62
Evotec Enters into Agreement with Antibiotic Research UK 63
Aptuit Enters into Agreement with Dimension Therapeutics 64
Trianni Enters into Agreement with Evotec 65
Evotec Forms Partnership with Ex Scientia 66
Evotec Partners with Pierre Fabre Labs 67
Icagen Partners with Aptuit 68
Evotec Partners with UCB 69
Evotec Extends its Agreement with Spero Therapeutics 70
Evotec Enters into Co-Development Agreement with Beyond Batten Disease Foundation 71
Evotec Enters into Research Agreement with Sanofi 72
Gladstone Institutes Enters into Joint Venture with Dolby Family Ventures and Evotec 73
Evotec Enters into Agreement with Facio Therapies 74
Second Genome Enters into Agreement with Evotec 75
SAMDI Tech Enters into Agreement with Exquiron 76
Evotec Enters into Research Agreement with C4X Discovery 77
Evotec Enters into Research Agreement with Ohio State University 78
Evotec Extends Research Agreement with C4X Discovery 79
Evotec to Enter into Co-Development Agreement with Sanofi 80
Evotec Enters into Research Agreement with C4X Discovery for NMR Technology 82
Rheumatech Enters into Development Agreement with Evotec 83
Euprotec Enters Into Agreement With Cantab Anti-infectives To Develop Antibiotics 84
Evotec Enters into Co-Development Agreement with Eternygen 85
Evotec Enters Into Agreement With Panion For Developing Chronic Pain Treatments 86
Evotec Enters into Agreement with Padlock Therapeutics 87
Evotec Extends Agreement with Padlock Therapeutics 88
Evotec Enters Into Research Agreement With Yale University For Cancer Therapy 89
Evotec Enters Into Co-Development Agreement With Johnson & Johnson 90
Evotec Enters Into Research Agreement With Leukemia & Lymphoma Society 91
Evotec Enters Into Research Agreement With Harvard University For Enteroendocrine Mechanisms 92
Evotec Enters Into Research Agreement With Harvard Stem Cell Institute For Amyotrophic Lateral Sclerosis 93
Evotec Enters Into Research Agreement With Harvard University To Develop Antibacterial Drugs 94
Evotec Enters Into Co-Development Agreement With Dana-Farber For Cancer Epigenetics 95
Evotec Enters Into Research Agreement With Apeiron Biologics For Cancer Immunotherapy 96
Evotec Enters Into Co-Development Agreement With Probiodrug For Glutaminyl Cyclase 97
Evotec Enters Into Agreement With Haplogen To Develop Drugs For Infectious Diseases 98
Apredica Enters Into Research Agreement With Pfizer 99
Bayer Extends its Co-Development Agreement with Evotec for Endometriosis Drugs 100
Evotec Enters Into Agreement With 4-Antibody For Antibody Detection 101
Evotec Enters Into Co-Development Agreement With IR Pharma 102
Evotec Enters Into Co-Development Agreement With Harvard University And BWH 103
Bayer Enters into Licensing Agreement with Haplogen and Evotec 105
Evotec Enters into Licensing Agreement with ERS Genomics 106
Evotec Enters into Licensing Agreement with Ncardia 107
Evotec Enters Into Licensing Agreement With Debiopharm 108
Evotec Enters Into Licensing Agreement With AstraZeneca For Kidney Disease Treatment 109
Evotec Enters Into Licensing Agreement With Janssen Pharma For NMDA Antagonists 110
Evotec Enters into Licensing Agreement with Broad Institute 112
Pfizer Enters into Licensing Agreement with Evotec 113
Cevec Pharma Enters Into Licensing Agreement With CCS Cell Culture Service 114
Cyprotex Enters Into Licensing Agreement With Sigma For Zinc Finger Nuclease Technology 115
Evotec And Harvard University Enter Into Licensing Agreement With Janssen Pharma For Beta-Cell Regeneration Candidates 116
Evotec Enters Into Licensing Agreement With Zhejiang Conba Pharma For EVT 401 118
Facio Therapies Raises USD5.4 Million in Equity Financing 119
Evotec to Raise USD96.4 Million in Private Placement of Shares 120
Evotec Receives Investment from Ellersbrook 121
Evotec Spin Out from Topas Therapeutics 122
Evotec Completes Private Placement Of Shares For US$40 Million 123
Catalent Pharma Completes Acquisition Of Clinical Trial Supplies Business From Aptuit For US$410 Million 125
Evotec Acquires Minority Stake in Exscientia for USD17.6 Million 126
Evotec Acquires Aptuit for USD300 Million 127
Evotec Acquires Cyprotex for USD68 Million 129
Aptuit Acquires Kuecept 131
Aptuit Acquires Exquiron Biotech 132
Albany Molecular Research Acquires SSCI from Aptuit for USD36 Million 133
Albany Molecular Research Acquires Aptuit Glasgow from Aptuit for USD24 Million 134
Evotec Acquires Euprotec 135
Evotec Acquires Bionamics, Asset Management Company 136
Apredica Acquires CeeTox, In-Vitro Toxicological Assays And Screening Data Provider, For Up To US$6 Million 137
Evotec Acquires CCS Cell Culture Service, Contract Research Organization 138
Evotec Acquires DeveloGen For USD18 Million 139
Evotec AG, Key Competitors 141
Evotec AG, Key Employees 142
Evotec AG, Subsidiaries 143
Evotec AG, Joint Venture 144
List of Figures
Evotec AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Evotec AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Evotec AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Evotec AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Evotec AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 9
Evotec AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 10
Evotec AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 11
Evotec AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 12
Evotec AG, Medical Devices Deals, 2012 to YTD 2018 14